Veradermics Surges 50% on Hair Loss Trial Results, Then Sells $213M in Stock
NEW YORK, April 28 —
Veradermics (MANE) rallied roughly 50% after reporting positive Phase 2/3 data for its hair loss drug, then immediately priced a $212.9M share sale.
- Stock surged approximately 44-50% on topline Phase 2/3 results for VDPHL01 in mild-to-moderate pattern hair loss
- Company priced a 3.35mn share offering raising ~$212.9M, with Suvretta Capital joining via private placement
- Forward P/E sits at -30.3x, confirming Veradermics is deeply pre-revenue and burning cash
What Actually Happened
Veradermics reported positive topline results from its Phase 2/3 trial of VDPHL01 for pattern hair loss. The stock ripped higher on the data. Before investors could finish celebrating, the company announced a public offering of 3.35mn shares at roughly $63.55 per share (that's the math on $212.9M for 3.35mn shares). At a current price near $100, that offering was priced at a discount of roughly 36% to where the stock was trading post-rally.
The timing is textbook biotech capital markets. You release the best data you've got, let the stock pop, then sell shares into the enthusiasm. Suvretta Capital's participation in the private placement alongside the public deal adds a credibility signal. Institutional money doesn't just chase headlines.
The Catch
Pattern hair loss is a massive addressable market. Finasteride and minoxidil have been the standard for decades, and investors have long salivated over a better mousetrap. But "positive topline results" is doing a lot of heavy lifting here. We don't have the full efficacy data, response rates, or safety profile yet. Topline readouts in dermatology have a habit of looking less impressive once the full dataset is published.
Then there's the dilution math. At 3.35mn new shares, existing shareholders just absorbed meaningful dilution. And the -30.3x forward P/E tells you the company has no revenue and significant losses ahead. That $212.9M buys runway, but an FDA filing, a commercial launch, and a sales force will cost multiples of that. This is not the last capital raise.
Bottom Line
The rally makes sense. Positive late-stage data in a big market deserves a re-rating. But buying at $100 when the company just sold shares at ~$63.55 means you're paying a 36% premium to what sophisticated investors paid hours ago. The smarter entry may come after the post-offering overhang settles and the full Phase 2/3 dataset drops. Watch for the complete efficacy publication and any FDA meeting disclosures. Those will determine whether VDPHL01 is a real product or a nice press release.
Veradermics doesn't have a Basis Report yet. Generate a full MANE analysis here to dig into the balance sheet and cash runway.
Basis Report does not hold positions in securities discussed. This is not investment advice.